Career progression is rarely linear, and there is no single path to leadership. In our latest blog, Sinéad McKeon discusses what drove her move from the lab bench to project management. She reflects on the capabilities...
Filter blogs
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Strategies for successful Integrated Summary of Efficacy and Safety (ISS/ISE) submissions
Developing an integrated summary of safety and efficacy (ISS/ISE) can be complex. This blog outlines practical strategies to organise data, plan efficiently and ensure compliant, high-quality submissions.
-
Smarter RBQM with intelligent tools
As clinical trials generate more data, learn how technology is the critical enabler for centralised monitoring and agile, risk-based quality management.
-
Reimagining clinical programming: the strategic role of R in modern trials
This blog explores how adopting R is transforming clinical programming by meeting growing complexity, tighter timelines, and the need for transparency, positioning it as a catalyst for innovation across pharma and biotech.
-
How GCP updates make way for an RBQM revolution
Explore how the new ICH GCP E6(R3) empowers sponsors and CROs to strategically innovate and optimise trials by embedding RBQM at the core of quality management.
-
A partnered perspective on the 2025 Medidata NEXT conference
ICON sponsored and presented at the 2025 Medidata NEXT conference in London, unveiling our Clinical Data Studio integration and discussing innovations in clinical data science and support efficient trials. Read key insights here.
-
Advancing pharmacovigilance in a changing landscape: 2024 World Drug Safety Congress
With over 1,500 registered attendees, the 2024 World Drug Safety Congress brought together pharmacovigilance experts to discuss the challenges and solutions in their profession. ICON experts who were there reflect on the topics discussed and look at the emerging trends.
-
How human-enabled AI is creating a new map for navigating site selection
Discover how AI transforms site selection in clinical research by leveraging data and human expertise through an ecosystem approach to optimise site ranking, patient enrolment, and study timelines.
-
Navigating the complexities of healthcare data types
Navigating the landscape of healthcare data has become increasingly challenging amidst a multitude of data types including open and closed claims sets. Choosing the appropriate foundational dataset will empower data-driven solutions to your business questions.
-
How AI could transform literature surveillance for pharmacovigilance
In pharmacovigilance AI could be used to detect adverse events sooner, offering benefits for patients and researchers.
-
-420x250.jpg?crop=yes&w=210&h=209&itok=DwbwT2wd "Affiliate model for pharmacovigilance operations")
Ensuring safety and compliance: the essentials of outsourcing pharmacovigilance
In this blog, we delve into the rationale behind outsourcing pharmacovigilance activities at the affiliate level and explore the essential requirements for appointing local persons for pharmacovigilance (LPPVs).
-
Safety reporting in LATAM is changing, are you ready?
LATAM is evolving to electronic safety reporting and it is essential to be prepared for it.
-
The impact of COVID-19 on pharmacovigilance
COVID-19 is affecting how clinical trials are managed, in terms of patient recruitment, patient care, data collection, analysis and safety reporting.
-
Towards a data-driven feasibility assessment
Explore how conducting a thorough data-driven feasibility assessment sets sponsors up for success in the operational aspects of their trials.
-
Controlling logistics costs can significantly reduce trial lab expenses
ICON has developed a lab logistics program to reduce costs
-
The final countdown to the overhaul of Pharmacovigilance in the EEA
In October, the European Medicines Agency (EMA) released their much anticipated Go-Live plan following input from all of the National Competent Authorities in the European Economic Area (EEA).
